13.75
Precedente Chiudi:
$13.31
Aprire:
$13.21
Volume 24 ore:
460.79K
Relative Volume:
2.06
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.00%
1M Prestazione:
+12.98%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Generate Biomedicines Inc Stock (GENB) Company Profile
Nome
Generate Biomedicines Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
GENB
Generate Biomedicines Inc
|
13.75 | 1.75B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Iniziato | Goldman | Buy |
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2026-03-24 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-24 | Iniziato | Piper Sandler | Overweight |
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Kailera Therapeutics files for US IPO - MarketScreener
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - Seeking Alpha
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - MarketScreener
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com
Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia
Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com
ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Free cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB | Generate Biomedicines, Inc. Common Stock Data, Price & News - Quiver Quantitative
Total debt per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Revenue per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Total liabilities & shareholders' equities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
After tax other income/expense of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Gross profit of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total revenue of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Average basic shares outstanding of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Pretax income of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Dividends – NASDAQ:GENB - TradingView
Net debt of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Tangible book value per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Cash from investing activities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Free cash flow of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines, Inc. Cash Flow – NASDAQ:GENB - TradingView
Long term debt to total assets ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Total liabilities of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBITDA ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to sales ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines Inc Azioni (GENB) Dati Finanziari
Non sono disponibili dati finanziari per Generate Biomedicines Inc (GENB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):